

# Newamsterdam Pharma Company N.v. (Fri, Jun 28, 2024)

Sell candidate since Jun 28, 2024

StockInvest.us  
Gyneju st. 14, "ROCKIT"  
Vilnius, LT-01109  
Lithuania



score: **-2.10**  
#20270/ 54216

Trend: Sell  
MV Long: Sell  
MV Short: Buy  
Pivot: Buy  
Volume: Buy  
MACD: Buy

## Tech commentaries:

The **Newamsterdam Pharma Company N.v.** stock price fell by **-1.69%** on the last day (Friday, 28th Jun 2024) from **\$19.54** to **\$19.21**. During the last trading day the stock fluctuated **4.33%** from a day low at **\$19.17** to a day high of **\$20.00**. The price has been going up and down for this period, and there has been a **-1.18%** loss for the last 2 weeks. Volume has increased on the last day by **303 thousand** shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, **388 thousand** shares were bought and sold for approximately **\$7.46 million**.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall **-10.25%** during the next 3 months and, with a 90% probability hold a price between **\$15.11** and **\$18.90** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

A buy signal was issued from a pivot bottom point on **Tuesday, June 18, 2024**, and so far it has risen 12.27%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The **Newamsterdam Pharma Company N.v.** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at **\$19.38**. On a fall, the stock will find some support from the short-term average at **\$19.01**. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

**Newamsterdam Pharma Company N.v.** finds support from accumulated volume at \$19.10 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at **\$19.50**, **\$19.80** and **\$19.86**.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved **\$0.83** between high and low, or **4.33%**. For the last week, the stock has had daily average volatility of **5.40%**.

**Newamsterdam Pharma Company N.v.** holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.

Risk: **Medium**

Evaluation: **Sell Candidate**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.